Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD1043 · 1 trial · 2 indications
To assess the safety and tolerability of a single or multiple doses of AZD1043 in healthy adult participants living with overweight and/or obesity, including participants of Japanese and Chinese descent.
| Arm | Type | Description |
|---|---|---|
| Part A1 (Global SAD): Cohort 1 - AZD1043 (Dose 1) | EXPERIMENTAL | Participants will receive a single dose of AZD1043 (Dose 1) or placebo. |
| Part A1 (Global SAD): Cohort 2 - AZD1043 (Dose 2) | EXPERIMENTAL | Participants will receive a single dose of AZD1043 (Dose 2) or placebo. |
| Part A1 (Global SAD): Cohort 3 - AZD1043 (Dose 3) | EXPERIMENTAL | Participants will receive a single dose of AZD1043 (Dose 3) or placebo. |
| Part A1 (Global SAD): Cohort 4 - AZD1043 (Dose 4) | EXPERIMENTAL | Participants will receive a single dose of AZD1043 (Dose 4) or placebo. |
| Part A1 (Global SAD): Cohort 5 - AZD1043 (Dose 5) | EXPERIMENTAL | Participants will receive a single dose of AZD1043 (Dose 5) or placebo. |
| Part A1 (Global SAD): Cohort 6 - AZD1043 (Dose 6) | EXPERIMENTAL | Participants will receive a single dose of AZD1043 (Dose 6) or placebo. |
| Part A2 (Japanese SAD): Cohort 1 - AZD1043 (Dose X) | EXPERIMENTAL | Japanese participants will receive a single dose of AZD1043 or placebo. |
| Part A2 (Japanese SAD): Cohort 2 - AZD1043 (Dose Y) | EXPERIMENTAL | Japanese participants will receive a single dose of AZD1043 or placebo. |
| Part A3 (Chinese SAD): Cohort 1 - AZD1043 (Dose Z) | EXPERIMENTAL | Chinese participants will receive a single dose of AZD1043 or placebo. |
| Part B1 (Global MAD): Cohort 1 - AZD1043 (Dose A) | EXPERIMENTAL | Participants will receive multiple doses of AZD1043 or placebo. |
| Part B1 (Global MAD): Cohort 2 - AZD1043 (Dose B) | EXPERIMENTAL | Participants will receive multiple doses of AZD1043 or placebo. |
| Part B1 (Global MAD): Cohort 3 - AZD1043 (Dose C) | EXPERIMENTAL | Participants will receive multiple doses of AZD1043 or placebo. |
| Part B2 (Japanese MAD): Cohort 1 - AZD1043 (Dose D) | EXPERIMENTAL | Japanese participants will receive multiple doses of AZD1043 or placebo. |
| Name | Type | Description |
|---|---|---|
| AZD1043 | DRUG | Single or multiple doses of AZD1043 will be administered. |
| Placebo | OTHER | Matching placebo to AZD1043 will be administered. |
Inclusion Criteria: * All females must have a negative pregnancy test at the Screening Visit and on admission to the Clinical Unit. * Females of non-childbearing potential must be confirmed as postmenopausal or have documentation of irreversible surgical sterilization by hysterectomy, bilateral oop...
AZD1043 is an investigational small molecule being developed for metabolic conditions. It is currently in a Phase 1 clinical trial studying its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adult participants living with overweight and/or obesity. The drug is not yet approved and remains in clinical development.
AZD1043 is being developed by AstraZeneca PLC, a biopharmaceutical company traded on the stock exchange under the ticker symbol AZN. The company is conducting a Phase 1 trial to evaluate the drug in healthy participants with overweight or obesity.
AZD1043 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The ongoing Phase 1 trial is recruiting participants to assess the drug's safety, tolerability, and how it is processed by the body.
AZD1043 is being studied in one active Phase 1 clinical trial with the identifier NCT07511205. This randomized, double-blind, controlled study is recruiting 104 healthy adult participants with overweight or obesity in the United States and United Kingdom. The trial is investigating the drug's safety, tolerability, pharmacokinetics, and pharmacodynamics.
Yes, AZD1043 is being studied in healthy volunteers. The Phase 1 clinical trial NCT07511205 is enrolling healthy adult participants aged 18 years and older who are living with overweight and/or obesity. The study is designed to evaluate the drug's safety, tolerability, and pharmacological effects in this population.